Poulton Jeffrey V.
SEC CIK 1782962 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| ALNY | ALNYLAM PHARMACEUTICALS, INC. | EVP, CFO | 63.1K | — | $8.59M | 33 | 2022-08-03 | 2026-03-04 |
Most active insiders at ALNY, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Greenstreet Yvonne | CEO, Dir | — | $24.46M |
| 2 | Fitzgerald Kevin Joseph | CSO, EVP, Head of Research | — | $10.74M |
| 3 | Garg Pushkal | EVP Chief R, D | — | $8.12M |
| 4 | Poulton Jeffrey V. | EVP, CFO | — | $4.95M |
| 5 | Tanguler Tolga | EVP, Chief Commercial Off | — | $3.06M |
| 6 | McLaughlin Melissa | CHRO | — | $1.27M |
| 7 | PYOTT DAVID E I | Dir | — | $1.15M |
| 8 | Reitan Colleen F | Dir | — | — |
| 9 | Sigal Charles Elliott | Dir | — | — |
| 10 | Arbuckle Stuart A | Dir | — | — |
Transactions 33
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2026-03-06 | 2026-03-04 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | Poulton Jeffrey V. | EVP, CFO | S - Sale | $323.08 | -2,468 | 63.1K | -4% | -$797.4K |
| DM | 2026-03-04 | 2026-03-02 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | Poulton Jeffrey V. | EVP, CFO | S - Sale | $327.65 | -2,206 | 64.9K | -3% | -$722.8K |
| D | 2026-03-04 | 2026-03-02 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | Poulton Jeffrey V. | EVP, CFO | A - Grant | $0.00 | +4,769 | 66.5K | +8% | $0 |
| D | 2026-03-02 | 2026-02-27 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | Poulton Jeffrey V. | EVP, CFO | M - OptEx | $0.00 | +1,908 | 61.7K | +3% | $0 |
| 2026-02-17 | 2026-02-12 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | Poulton Jeffrey V. | EVP, CFO | A - Grant | $0.00 | +4,579 | 62.0K | +8% | $0 | |
| 2026-02-17 | 2026-02-13 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | Poulton Jeffrey V. | EVP, CFO | S - Sale | $310.08 | -2,242 | 59.8K | -4% | -$695.2K | |
| 2026-01-14 | 2026-01-11 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | Poulton Jeffrey V. | EVP, CFO | A - Grant | $0.00 | +6,193 | 60.2K | +11% | $0 | |
| M | 2026-01-14 | 2026-01-12 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | Poulton Jeffrey V. | EVP, CFO | S - Sale | $362.87 | -2,780 | 57.5K | -5% | -$1.01M |
| M | 2025-10-03 | 2025-10-02 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | Poulton Jeffrey V. | EVP, CFO | S - Sale | $452.05 | -3,821 | 54.3K | -7% | -$1.73M |
| M | 2025-10-03 | 2025-10-01 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | Poulton Jeffrey V. | EVP, CFO | A - Grant | $0.00 | +7,752 | 57.9K | +15% | $0 |
| M | 2025-08-19 | 2025-08-18 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | Poulton Jeffrey V. | EVP, CFO | S - Sale | $453.27 | -2,274 | 50.1K | -4% | -$1.03M |
| 2025-08-19 | 2025-08-15 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | Poulton Jeffrey V. | EVP, CFO | A - Grant | $0.00 | +4,644 | 52.4K | +10% | $0 | |
| DM | 2025-03-05 | 2025-03-03 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | Poulton Jeffrey V. | EVP, CFO | S - Sale | $243.78 | -1,264 | 48.7K | -3% | -$308.1K |
| D | 2025-03-05 | 2025-03-03 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | Poulton Jeffrey V. | EVP, CFO | A - Grant | $0.00 | +15.1K | 49.0K | +45% | $0 |
| D | 2025-03-03 | 2025-02-27 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | Poulton Jeffrey V. | EVP, CFO | M - OptEx | $0.00 | +1,908 | 34.7K | +6% | $0 |
| DM | 2025-03-03 | 2025-02-28 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | Poulton Jeffrey V. | EVP, CFO | S - Sale+OE | $241.70 | -796 | 33.9K | -2% | -$192.4K |
| 2025-02-18 | 2025-02-13 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | Poulton Jeffrey V. | EVP, CFO | A - Grant | $0.00 | +3,109 | 33.8K | +10% | $0 | |
| M | 2025-02-18 | 2025-02-14 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | Poulton Jeffrey V. | EVP, CFO | S - Sale | $255.17 | -967 | 32.8K | -3% | -$246.7K |
| M | 2024-11-27 | 2024-11-26 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | Poulton Jeffrey V. | EVP, CFO | S - Sale | $250.98 | -1,682 | 30.7K | -5% | -$422.1K |
| 2024-11-27 | 2024-11-25 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | Poulton Jeffrey V. | EVP, CFO | A - Grant | $0.00 | +3,434 | 32.3K | +12% | $0 | |
| 2024-06-26 | 2024-06-24 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | Poulton Jeffrey V. | EVP, CFO | A - Grant | $0.00 | +3,278 | 30.5K | +12% | $0 | |
| M | 2024-06-26 | 2024-06-25 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | Poulton Jeffrey V. | EVP, CFO | S - Sale | $231.00 | -1,605 | 30.0K | -5% | -$370.7K |
| D | 2024-03-05 | 2024-03-01 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | Poulton Jeffrey V. | EVP, CFO | A - Grant | $0.00 | +7,741 | 27.2K | +40% | $0 |
| DM | 2024-02-29 | 2024-02-28 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | Poulton Jeffrey V. | EVP, CFO | S - Sale+OE | $155.30 | -574 | 19.8K | -3% | -$89.1K |
| D | 2024-02-29 | 2024-02-27 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | Poulton Jeffrey V. | EVP, CFO | M - OptEx | $0.00 | +1,908 | 20.1K | +11% | $0 |
| M | 2024-02-20 | 2024-02-16 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | Poulton Jeffrey V. | EVP, CFO | S - Sale | $148.06 | -1,007 | 18.1K | -5% | -$149.1K |
| 2024-02-20 | 2024-02-15 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | Poulton Jeffrey V. | EVP, CFO | A - Grant | $0.00 | +3,278 | 19.2K | +21% | $0 | |
| M | 2023-08-07 | 2023-08-04 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | Poulton Jeffrey V. | EVP, CFO | S - Sale | $185.85 | -3,460 | 18.7K | -16% | -$643.0K |
| M | 2023-08-07 | 2023-08-03 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | Poulton Jeffrey V. | EVP, CFO | A - Grant | $0.00 | +7,627 | 19.3K | +65% | $0 |
| M | 2023-04-28 | 2023-04-27 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | Poulton Jeffrey V. | EVP, CFO | S - Sale | $194.59 | -977 | 12.6K | -7% | -$190.1K |
| 2023-04-28 | 2023-04-26 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | Poulton Jeffrey V. | EVP, CFO | A - Grant | $0.00 | +3,277 | 12.7K | +35% | $0 | |
| M | 2022-08-05 | 2022-08-04 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | Poulton Jeffrey V. | EVP, CFO | F - Tax | $191.69 | -5,054 | 9,406 | -35% | -$968.8K |
| M | 2022-08-05 | 2022-08-03 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | Poulton Jeffrey V. | EVP, CFO | A - Grant | $0.00 | +11.3K | 7,653 | New | $0 |
Purchase Sale Sale after option exercise All abbreviations